Since winning approval for use in psoriasis in September 2014, Otezla has steadily been chipping away at U.S. market share in the indication, turning into a billion-dollar blockbuster in the process. Otezla’s sales continued climbing throughout 2016, and with launches planned in new international markets soon, sales could head even higher.
Category: Enbrel, Etanercept (generic)
How Big Is the Opportunity for Celgene’s Otezla Overseas?
Since winning approval for use in psoriasis in September 2014, Otezla has steadily been chipping away at U.S. market share in the indication, turning into a billion-dollar blockbuster in the process. Otezla’s sales continued climbing throughout 2016, and with launches planned in new international markets soon, sales could head even higher.
The 3 Biggest Risks for Pfizer in 2017
Could the new year present better opportunities for the big pharma? Yes, but challenges remain. Here are three of Pfizer’s biggest risks in 2017.